Senior Vice President and Head of Global CNS Disease Research at Boehringer Ingelheim, Dr Hugh Marston originally trained in experimental psychopharmacology at the University of Cambridge. After a fellowship at NIDA, he spent 25 years in Scotland, first at the University of Edinburgh, then at Organon Pharmaceuticals as Head of Neurobiology. The Organon neuropsychiatry team, acquired by Schering-Plough then Merck, brought asenapine and sugammadex to market, along with a range of innovative programs into manufacture. He then headed Pharmacology at IOmet Pharma, a micro-pharma company acquired by Merck, having developed clinic-ready packages from scratch. Hugh then headed Translational Neuroscience at Lilly, Erl Wood, before moving to his current role at BI. The BI CNS team, using a circuits-and-systems approach, has an extensive neuropsychiatry pipeline aiming to deliver a new precision in psychiatry. BI’s “breakthrough”-designated iclepertin (GlyT1 inhibitor) is in Phase III for cognitive impairment in schizophrenia. With his long-standing interest in transforming translation from and to the clinic, Hugh has led, from inception, the IMI2 PRISM1 & 2 initiatives seeking transdiagnostic, quantitative biological phenotypes in CNS disorders. He maintains an active interest in academic research through collaborations with UK, European, and US universities and institutions.

Moderator Of 1 Session

Session Type
Industry
Date
Sun, 05.06.2022
Session Time
13:00 - 14:00
Room
Industry session hall 2
Session Description
The PRISM Project: A Window Into the Future of Precision Psychiatry- Supported by Boehringer Ingelheim

Session Description:

We are on the cusp of a paradigm shift with the emerging field of precision psychiatry. Research in this area is aimed at improving understanding of psychiatric illnesses by leveraging insights from many techniques and accounting for patient individuality. The ultimate goal is to positively impact clinical practice and transform the lives of patients living with mental health conditions. With the concept of precision psychiatry as a backdrop, the Psychiatric Ratings using Intermediate Stratified Markers (PRISM) project was born. This session will take you through the PRISM journey—from conception through completion of PRISM 1 and launch of PRISM 2—and highlight how this project is taking meaningful steps to translate the idea of precision psychiatry into clinical practice. The PRISM project used social withdrawal as a primary focus as it represents an unmet need in the treatment of mental health disorders and can be particularly burdensome for patients. This session will introduce you to an innovative approach to monitoring social function and walk you through a live demonstration of the novel technology, providing a tangible example of how it may be used as a scalable digital biomarker for stratifying patients, and how it applies to the transdiagnostic approach.

Session Icon
Fully Live

Presenter Of 3 Presentations

The PRISM Journey: From Concept to Completion

Session Type
Industry
Date
Sun, 05.06.2022
Session Time
13:00 - 14:00
Room
Industry session hall 2
Session Icon
Fully Live
Lecture Time
13:00 - 13:15

Audience Q&A

Session Type
Industry
Date
Sun, 05.06.2022
Session Time
13:00 - 14:00
Room
Industry session hall 2
Session Icon
Fully Live
Lecture Time
13:45 - 13:55

Summary and Close

Session Type
Industry
Date
Sun, 05.06.2022
Session Time
13:00 - 14:00
Room
Industry session hall 2
Session Icon
Fully Live
Lecture Time
13:55 - 14:00